Clinical Trials on Glioma Glioblastoma Multiforme in Hong Kong

Total 57 results

Center Trials & Treatment

Withdrawn

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Gliosarcoma | Recurrent Glioblastoma | Anaplastic Gliomas

Singapore, Hong Kong
Center Trials & Treatment

No longer available

Expanded Access for Pembrolizumab (MK-3475)

Glioblastoma Multiforme | Melanoma (Skin) | Melanoma Recurrent | Glioma of Brain | Glioblastoma by Gene Expression Profile

Hong Kong, Belarus, Tajikistan, Uzbekistan
The University of Hong Kong

Recruiting

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd (TAC-GReD)

Recurrent Glioblastoma | Recurrent Glioma | Poly ADP Ribose Polymerase (PARP) Inhibitor | PTEN Gene Inactivation | IDH Mutation

Hong Kong
Pfizer

Terminated

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Advanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)

United States, Spain, Hong Kong, Belgium, Australia, France
Incheon St.Mary's Hospital
National Cancer Center, Korea

Unknown

Procarbazine and Lomustine in Recurrent Glioblastoma

Recurrent Glioblastoma Multiforme

Korea, Republic of
TJ Biopharma Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Newly Diagnosed Glioblastoma

China, Hong Kong
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Breast Cancer | Colorectal Cancer | Solid Tumor | Glioblastome Multiforme

United States
Novartis Pharmaceuticals

Completed

An East Asian Study of LDE225

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Taiwan, Hong Kong, Japan
Celldex Therapeutics

Completed

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

Glioblastoma | Gliosarcoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component

United States, Canada, Australia, Israel, Taiwan, United Kingdom, Belgium, France, Spain, Germany, Austria, Brazil, Colombia, Czechia, Greece, Hungary, India, Italy, Mexico, Netherlands, New Zealand, Peru, Switzerland, Thailand
Hoffmann-La Roche

Completed

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

United States, United Kingdom, Belgium, Denmark, Korea, Republic of, Poland, Spain, Canada, Sweden, Russian Federation, Australia, Greece, Portugal, France, Netherlands, New Zealand, Switzerland, Germany, Hong Kong, Hungary, Israel and more
National Cancer Institute (NCI)

Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Australia, New Zealand, Canada
National Cancer Institute (NCI)
NRG Oncology; Radiation Therapy Oncology Group

Completed

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma | Supratentorial Glioblastoma

United States, Canada, Israel
National Cancer Institute (NCI)

Active, not recruiting

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma

United States, Canada, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | WHO Grade 3 Glioma

United States, Puerto Rico
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Glioma | Cholangiocarcinoma | Chondrosarcoma | Any Solid Tumor

United States, Spain, Korea, Republic of, Australia, Japan, Taiwan, France, Singapore, Hong Kong
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States, Canada
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Neurofibromatosis Type 1 | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Childhood Visual Pathway Glioma

United States, Canada, Australia, New Zealand
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas

Brain and Central Nervous System Tumors

Canada, United States
National Cancer Institute (NCI)

Completed

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Cerebral Anaplastic Astrocytoma | Cerebral Astrocytoma | Childhood Cerebellar Anaplastic Astrocytoma

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI); Pediatric Oncology Group

Completed

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Brain Tumors | Central Nervous System Tumors

United States, Puerto Rico, Switzerland, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Medulloblastoma | Anaplastic Medulloblastoma

United States, Canada, Puerto Rico, Australia, Netherlands
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Recurrent Childhood Ependymoma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Subependymal Giant Cell Astrocytoma | Childhood Mixed Glioma | Childhood Oligodendroglioma and other conditions

United States, Canada, Australia
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Medulloblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Suspended

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Medulloblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Untreated Childhood Medulloblastoma

United States, Canada, Australia, New Zealand, Switzerland, Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Ependymoma | Anaplastic Ependymoma | Clear Cell Ependymoma | Brain Ependymoma | Cellular Ependymoma | Papillary Ependymoma

United States, Canada, Australia, New Zealand
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Pfizer
Children's Oncology Group (COG)

Active, not recruiting

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Ewing Sarcoma | Medulloblastoma | Rhabdoid Tumor | Neuroblastoma | Solid Tumors | Rhabdomyosarcoma | Diffuse Intrinsic Pontine Glioma

United States, Canada, India, Spain, United Kingdom, Belgium, Hungary, Brazil, Slovakia, Poland, Argentina, Bulgaria, Korea, Republic of, Czechia, Germany, Israel, Netherlands, France, Italy, Sweden, Turkey
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Brain Tumor | Central Nervous System Tumor

United States, Canada, Australia, Switzerland, Netherlands, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy in Treating Young Patients With Gliomas

Brain Tumor | Central Nervous System Tumor

United States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise Specified

United States, Canada, Australia, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma

Brain and Central Nervous System Tumors

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Ependymoma | Childhood Craniopharyngioma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Brain Tumors | Central Nervous System Tumors

United States, Canada, Australia, Switzerland, Netherlands, New Zealand
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada

Clinical Trials on Glioma Glioblastoma Multiforme in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations